Agilent Technologies Stock Price, News & Analysis

Agilent Technologies Inc. (NYSE: A) is a global company in the field of analytical and clinical laboratory technologies. The company describes itself as delivering insights and innovation that help customers "bring great science to life." Agilent offers a full range of solutions that include instruments, software, services, and expertise, which are used to provide trusted answers to customers’ most challenging scientific and analytical questions.

According to its public materials, Agilent’s technologies support laboratories and organizations across life sciences, diagnostics, and applied markets. The company is associated with the analytical laboratory instrument manufacturing industry within the broader manufacturing sector. Its measurement and laboratory technologies are used in areas such as biopharmaceutical and chemical applications, advanced materials, clinical laboratories, environmental analysis, forensics, food-related testing, academic research, and government-related organizations, as described in historical overviews of the business.

Agilent states that it operates on a global scale and employs approximately 18,000 people worldwide. The company reports that it generated revenue of $6.95 billion in its fiscal year ended October 31, 2025, and $6.51 billion in fiscal year 2024. These figures underscore the scale of its operations in the laboratory technology and diagnostics markets. Agilent’s common stock is registered under the symbol A on the New York Stock Exchange.

Business focus and solutions

Agilent describes its offering as a full range of laboratory-focused solutions. These include analytical instruments, software for data handling and analysis, and a variety of services and expertise that support customers across the lifecycle of their scientific and analytical workflows. The company emphasizes that its solutions are intended to provide reliable, trusted answers in complex laboratory environments, from research through applied and regulated settings.

In its communications, Agilent highlights its role in life sciences and diagnostics. The company has referenced three operating groups in its financial reporting: the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These groups reflect how Agilent organizes its activities across different laboratory markets and service models, including instruments, consumables, and service-oriented offerings.

Life Sciences and Diagnostics Markets Group

The Life Sciences and Diagnostics Markets Group (LDG) focuses on markets related to life sciences research and diagnostic applications. In its financial disclosures, Agilent reports revenue and operating margin for this group, indicating that it is a distinct operating segment. LDG’s activities relate to technologies and solutions used in life science laboratories and diagnostic settings, where accurate measurement and analysis are critical.

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) is reported as another operating segment. Agilent associates this group with revenue from activities that extend beyond instruments alone, including services and other offerings that support laboratory operations. In its segment reporting, the company presents ACG revenue and operating margins separately, indicating that this group plays a specific role in its overall business model and customer engagement.

Applied Markets Group

The Applied Markets Group (AMG) is the third operating group highlighted in Agilent’s financial reports. This group addresses applied markets, which can include areas such as chemical analysis, advanced materials, and other non-clinical applications where analytical laboratory technologies are required. Agilent reports AMG’s revenue and operating margin, underscoring its contribution to the company’s diversified participation in analytical and applied science markets.

Regulated and GMP-related environments

Agilent also develops software and systems that address regulatory requirements in laboratory and manufacturing environments. For example, the company has announced 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This software includes a compliance license and enhanced security features, with capabilities such as secure user authentication, electronic signatures, and complete audit trails. Agilent states that these features are intended to support deployment of the RTCA eSight system in GMP-regulated manufacturing and quality control settings, in addition to its use in drug discovery and development laboratories.

By adding Part 11 compliance and security features to the xCELLigence RTCA eSight platform, Agilent indicates that it aims to support continuity from early-stage drug discovery and research through to production. The company describes this as helping users ensure that electronic records and audit trails are trustworthy, attributable, and compliant with regulatory expectations in biopharma and cell therapy manufacturing environments.

Chromatography and biotherapeutics applications

Agilent has also announced products in the area of liquid chromatography for biotherapeutics. The company introduced Agilent Altura Ultra Inert HPLC Columns, which it describes as high performance liquid chromatography columns suited for biotherapeutics applications. According to Agilent, these columns are designed for demanding applications including peptide GLP-1 and oligonucleotide therapeutic development and quality control.

In its description of the Altura Ultra Inert HPLC Columns, Agilent highlights attributes such as faster conditioning, improved peak shape, and enhanced sensitivity. The company associates these columns with its proprietary Ultra Inert technology and positions them as part of a broader inert sample flow path portfolio. Agilent presents this launch as reinforcing its focus on products that support the development and production of high-quality therapeutics in the biopharmaceutical sector.

Financial reporting and segment information

Agilent’s SEC filings and press releases provide insight into its financial structure and reporting practices. The company reports consolidated financial results, including net revenue, costs and expenses, income from operations, and net income. It also discloses segment-level revenue and operating margins for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group.

Agilent uses both GAAP and non-GAAP financial measures in its communications. In its Form 8-K filings regarding quarterly results, the company explains that it provides non-GAAP financial information to offer supplemental insight into operational performance. It notes that these non-GAAP measures exclude items such as restructuring and amortization, and that management uses them for internal comparisons and to evaluate performance relative to historical results and other companies. Agilent also states that non-GAAP information is not an alternative to GAAP and may differ from similar measures used by other companies.

Capital markets and shareholder returns

Agilent’s common stock is registered on the New York Stock Exchange under the symbol A. The company has announced cash dividends on its common stock, stating, for example, a quarterly dividend amount and record and payment dates in its public news releases. Agilent notes that the timing and amounts of future dividends are subject to determination and approval by its board of directors, indicating a board-governed approach to capital return decisions.

In addition to dividends, Agilent’s financial statements and cash flow information show activities such as repurchases of common stock, issuance and repayment of long-term debt, and investments in property, plant, and equipment. These disclosures illustrate how the company allocates capital among operations, shareholder returns, and investment in its asset base.

Corporate governance and leadership changes

Agilent reports changes in its senior leadership through Form 8-K filings. For example, the company has disclosed the resignation of a chief financial officer, the appointment of an interim CFO, and later the appointment of a new senior vice president and chief financial officer and principal financial officer. These filings include information about the appointees’ prior roles, compensation arrangements, and equity awards, as well as references to change-of-control agreements and stock plans. Through these disclosures, Agilent provides transparency into its governance processes and executive compensation structures.

Use of Agilent technologies

Across its public communications, Agilent emphasizes that its instruments, software, services, and expertise are used to address complex analytical challenges in laboratories worldwide. The company positions its technologies as tools that enable customers to generate reliable data, support regulatory compliance where required, and advance scientific discovery and product development in fields such as life sciences, diagnostics, and biopharmaceutical manufacturing.